Search

Your search keyword '"Attard G."' showing total 902 results
Start Over Author "Attard G."
902 results on '"Attard G."'

4. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Author

Sutera, P.A., Shetty, A.C., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., Chang, J., Fonteyne, V., Mendes, A.A., Lumen, N., Delrue, L., Verbeke, S., De Man, K., Rana, Z., Hodges, T., Hamid, A., Roberts, N., Song, D.Y., Pienta, K., Ross, A.E., Feng, F., Joniau, S., Spratt, D., Gillessen, S., Attard, G., James, N.D., Lotan, T., Davicioni, E., Sweeney, C., Tran, P.T., Deek, M.P., and Ost, P.

Published
2023
Full Text
View/download PDF

5. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Author

Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., Corral, A. del, Francis, P., Kim, W., and Efstathiou, E.

Published
2023
Full Text
View/download PDF

8. Fracture-related hospitalisations in de novo advanced or metastatic hormone-sensitive prostate cancer: Secondary analysis of the STAMPEDE abiraterone acetate plus prednisone +/- enzalutamide and M1|RT phase 3 trials using health systems data

Author

Jones, C., primary, Dutey-Magni, P., additional, Murphy, L., additional, Murray, M., additional, Brown, J., additional, Mccloskey, E., additional, Parmar, M.K.B., additional, Parker, C., additional, Attard, G., additional, James, N.D., additional, Sydes, M.R., additional, Brown, L.C., additional, Clarke, N.W., additional, and Sachdeva, A., additional

Published
2024
Full Text
View/download PDF

12. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse

Author

Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A., Prekovic, S., Wetterskog, D., Tolonen, T., Vuorinen, E. M., Kiviaho, A., Nätkin, R., Häkkinen, T., Devlies, W., Henttinen, S., Kaarijärvi, R., Lahnalampi, M., Kaljunen, H., Nowakowska, K., Syvälä, H., Bläuer, M., Cremaschi, P., Claessens, F., Visakorpi, T., Tammela, T. L. J., Murtola, T., Granberg, K. J., Lamb, A. D., Ketola, K., Mills, I. G., Attard, G., Wang, W., Nykter, M., and Urbanucci, A.

Published
2021
Full Text
View/download PDF

14. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Author

Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., and James, N.D.

Published
2019
Full Text
View/download PDF

15. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

Author

Hasan, A, Cremaschi, P, Wetterskog, D, Jayaram, A, Wong, S, Williams, S, Pasam, A, Trigos, A, Trujillo, B, Grist, E, Friedrich, S, Vainauskas, O, Parry, M, Ismail, M, Devlies, W, Wingate, A, Linch, M, Naceur-Lombardelli, C, Zaccaria, S, Hessey, S, Shiu, K, Bridgewater, J, Hochhauser, D, Forster, M, Lee, S, Ahmad, T, Papadatos-Pastos, D, Janes, S, Van Loo, P, Enfield, K, Mcgranahan, N, Huebner, A, Quezada, S, Beck, S, Parker, P, Enver, T, Hynds, R, Pearce, D, Falzon, M, Proctor, I, Sinclair, R, Lok, C, Rhodes, Z, Moore, D, Marafioti, T, Mitchison, M, Ellery, P, Sivakumar, M, Brandner, S, Rowan, A, Hiley, C, Veeriah, S, Shaw, H, Toncheva, A, Prymas, P, Watkins, T, Bailey, C, Martinez Ruiz, C, Litchfield, K, Al-Bakir, M, Kanu, N, Ward, S, Lim, E, Reading, J, Chain, B, Akay, M, Flanagan, A, Biswas, D, Pich, O, Dietzen, M, Puttick, C, Colliver, E, Magness, A, Angelova, M, Black, J, Lucas, O, Hill, W, Liu, W, Frankell, A, Magno, N, Athanasopoulou, F, Salgado, R, Lee, C, Grigoriadis, K, Al-Sawaf, O, Karasaki, T, Bunkum, A, Noorani, I, Benafif, S, Barbe, V, Bola, S, Leone, G, Alifrangis, C, Mcgovern, U, Thol, K, Gamble, S, Ung, S, Sahwangarrom, T, Marin, C, Pawlik, P, Lam, J, Richard, C, Vendramin, R, Dijkstra, K, Rane, J, Nicod, J, Dwornik, A, Bowles, K, Zaidi, R, Gishen, F, Stone, P, Stirling, C, Turajlic, S, Larkin, J, Pickering, L, Furness, A, Young, K, Drake, W, Edmonds, K, Hunter, N, Mangwende, M, Pearce, K, Grostate, L, Au, L, Spain, L, Shepherd, S, Yan, H, Shum, B, Tippu, Z, Hanley, B, Spencer, C, Emmerich, M, Gerard, C, Schmitt, A, Del Rosario, L, Carlyle, E, Lewis, C, Holt, L, Lucanas, A, O'Flaherty, M, Hazell, S, Mudhar, H, Messiou, C, Latifoltojar, A, Fendler, A, Byrne, F, Pallikonda, H, Lobon, I, Coulton, A, Cattin, A, Deng, D, Feng, H, Yousaf, N, Popat, S, Curtis, O, Milner-Watts, C, Stamp, G, Nye, E, Murra, A, Korteweg, J, Kelly, D, Terry, L, Biano, J, Peat, K, Kelly, K, Grieco, C, Le, M, D'Arienzo, P, Turay, E, Hill, P, Josephs, D, Irshad, S, Spicer, J, Mahadeva, U, Green, A, Stewart, R, Wright, N, Pulman, G, Mitu, R, Phillips-Boyd, S, Enting, D, Rudman, S, Ghosh, S, Karapanagiotou, E, Pintus, E, Tutt, A, Howlett, S, Brenton, J, Caldas, C, Fitzgerald, R, Jimenez-Linan, M, Provenzano, E, Cluroe, A, Paterson, A, Aitken, S, Allinson, K, Stewart, G, Mcdermott, U, Beddowes, E, Maughan, T, Ansorge, O, Campbell, P, Roxburgh, P, Fraser, S, Blyth, K, Le Quesne, J, Krebs, M, Blackhall, F, Summers, Y, Oliveira, P, Ortega-Franco, A, Dive, C, Gomes, F, Carter, M, Dransfield, J, Thomas, A, Fennell, D, Shaw, J, Wilson, C, Marrone, D, Naidu, B, Baijal, S, Tanchel, B, Langman, G, Robinson, A, Collard, M, Cockcroft, P, Ferris, C, Bancroft, H, Kerr, A, Middleton, G, Webb, J, Kadiri, S, Colloby, P, Olisemeke, B, Wilson, R, Shackleford, H, Osman, A, Tomlinson, I, Jogai, S, Holden, S, Fernandes, T, Mcneish, I, Hampton, B, Mckenzie, M, Hackshaw, A, Sharp, A, Chan, K, Farrelly, L, Bridger, H, Leslie, R, Tookman, A, Swanton, C, Jamal-Hanjani, M, Lise, S, Sandhu, S, Attard, G, Hasan A. M. M., Cremaschi P., Wetterskog D., Jayaram A., Wong S. Q., Williams S., Pasam A., Trigos A., Trujillo B., Grist E., Friedrich S., Vainauskas O., Parry M., Ismail M., Devlies W., Wingate A., Linch M., Naceur-Lombardelli C., Zaccaria S., Hessey S., Shiu K. -K., Bridgewater J., Hochhauser D., Forster M., Lee S. -M., Ahmad T., Papadatos-Pastos D., Janes S., Van Loo P., Enfield K., McGranahan N., Huebner A., Quezada S., Beck S., Parker P., Enver T., Hynds R. E., Pearce D. R., Falzon M., Proctor I., Sinclair R., Lok C. -W., Rhodes Z., Moore D., Marafioti T., Mitchison M., Ellery P., Sivakumar M., Brandner S., Rowan A., Hiley C., Veeriah S., Shaw H., Toncheva A., Prymas P., Watkins T. B. K., Bailey C., Martinez Ruiz C., Litchfield K., Al-Bakir M., Kanu N., Ward S., Lim E., Reading J., Chain B., Watkins T., Akay M., Flanagan A., Biswas D., Pich O., Dietzen M., Puttick C., Colliver E., Magness A., Angelova M., Black J., Lucas O., Hill W., Liu W. -K., Frankell A., Magno N., Athanasopoulou F., Salgado R., Lee C., Grigoriadis K., Al-Sawaf O., Karasaki T., Bunkum A., Noorani I., Benafif S., Barbe V., Bola S. K., Leone G., Alifrangis C., McGovern U., Thol K., Gamble S., Ung S. K., Sahwangarrom T., Marin C. P., Wong S., Pawlik P., Lam J. M., Richard C., Vendramin R., Dijkstra K., Rane J., Nicod J., Dwornik A., Bowles K., Zaidi R., Gishen F., Stone P., Stirling C., Turajlic S., Larkin J., Pickering L., Furness A., Young K., Drake W., Edmonds K., Hunter N., Mangwende M., Pearce K., Grostate L., Au L., Spain L., Shepherd S., Yan H., Shum B., Tippu Z., Hanley B., Spencer C., Emmerich M., Gerard C., Schmitt A. M., Del Rosario L., Carlyle E., Lewis C., Holt L., Lucanas A., O'Flaherty M., Hazell S., Mudhar H., Messiou C., Latifoltojar A., Fendler A., Byrne F., Pallikonda H., Lobon I., Coulton A., Cattin A. -L., Deng D., Feng H., Yousaf N., Popat S., Curtis O., Milner-Watts C., Stamp G., Nye E., Murra A., Korteweg J., Kelly D., Terry L., Biano J., Peat K., Kelly K., Grieco C., Le M. L., D'Arienzo P. D., Turay E., Hill P., Josephs D., Irshad S., Spicer J., Mahadeva U., Green A., Stewart R., Wright N., Pulman G., Mitu R., Phillips-Boyd S., Enting D., Rudman S., Ghosh S., Karapanagiotou E., Pintus E., Tutt A., Howlett S., Brenton J., Caldas C., Fitzgerald R., Jimenez-Linan M., Provenzano E., Cluroe A., Paterson A., Aitken S., Allinson K., Stewart G., McDermott U., Beddowes E., Maughan T., Ansorge O., Campbell P., Roxburgh P., Fraser S., Blyth K., Le Quesne J., Krebs M., Blackhall F., Summers Y., Oliveira P., Ortega-Franco A., Dive C., Gomes F., Carter M., Dransfield J., Thomas A., Fennell D., Shaw J., Wilson C., Marrone D., Naidu B., Baijal S., Tanchel B., Langman G., Robinson A., Collard M., Cockcroft P., Ferris C., Bancroft H., Kerr A., Middleton G., Webb J., Kadiri S., Colloby P., Olisemeke B., Wilson R., Shackleford H., Osman A., Tomlinson I., Jogai S., Holden S., Fernandes T., McNeish I., Hampton B., McKenzie M., Hackshaw A., Sharp A., Chan K., Farrelly L., Bridger H., Leslie R., Tookman A., Swanton C., Jamal-Hanjani M., Lise S., Sandhu S., Attard G., Hasan, A, Cremaschi, P, Wetterskog, D, Jayaram, A, Wong, S, Williams, S, Pasam, A, Trigos, A, Trujillo, B, Grist, E, Friedrich, S, Vainauskas, O, Parry, M, Ismail, M, Devlies, W, Wingate, A, Linch, M, Naceur-Lombardelli, C, Zaccaria, S, Hessey, S, Shiu, K, Bridgewater, J, Hochhauser, D, Forster, M, Lee, S, Ahmad, T, Papadatos-Pastos, D, Janes, S, Van Loo, P, Enfield, K, Mcgranahan, N, Huebner, A, Quezada, S, Beck, S, Parker, P, Enver, T, Hynds, R, Pearce, D, Falzon, M, Proctor, I, Sinclair, R, Lok, C, Rhodes, Z, Moore, D, Marafioti, T, Mitchison, M, Ellery, P, Sivakumar, M, Brandner, S, Rowan, A, Hiley, C, Veeriah, S, Shaw, H, Toncheva, A, Prymas, P, Watkins, T, Bailey, C, Martinez Ruiz, C, Litchfield, K, Al-Bakir, M, Kanu, N, Ward, S, Lim, E, Reading, J, Chain, B, Akay, M, Flanagan, A, Biswas, D, Pich, O, Dietzen, M, Puttick, C, Colliver, E, Magness, A, Angelova, M, Black, J, Lucas, O, Hill, W, Liu, W, Frankell, A, Magno, N, Athanasopoulou, F, Salgado, R, Lee, C, Grigoriadis, K, Al-Sawaf, O, Karasaki, T, Bunkum, A, Noorani, I, Benafif, S, Barbe, V, Bola, S, Leone, G, Alifrangis, C, Mcgovern, U, Thol, K, Gamble, S, Ung, S, Sahwangarrom, T, Marin, C, Pawlik, P, Lam, J, Richard, C, Vendramin, R, Dijkstra, K, Rane, J, Nicod, J, Dwornik, A, Bowles, K, Zaidi, R, Gishen, F, Stone, P, Stirling, C, Turajlic, S, Larkin, J, Pickering, L, Furness, A, Young, K, Drake, W, Edmonds, K, Hunter, N, Mangwende, M, Pearce, K, Grostate, L, Au, L, Spain, L, Shepherd, S, Yan, H, Shum, B, Tippu, Z, Hanley, B, Spencer, C, Emmerich, M, Gerard, C, Schmitt, A, Del Rosario, L, Carlyle, E, Lewis, C, Holt, L, Lucanas, A, O'Flaherty, M, Hazell, S, Mudhar, H, Messiou, C, Latifoltojar, A, Fendler, A, Byrne, F, Pallikonda, H, Lobon, I, Coulton, A, Cattin, A, Deng, D, Feng, H, Yousaf, N, Popat, S, Curtis, O, Milner-Watts, C, Stamp, G, Nye, E, Murra, A, Korteweg, J, Kelly, D, Terry, L, Biano, J, Peat, K, Kelly, K, Grieco, C, Le, M, D'Arienzo, P, Turay, E, Hill, P, Josephs, D, Irshad, S, Spicer, J, Mahadeva, U, Green, A, Stewart, R, Wright, N, Pulman, G, Mitu, R, Phillips-Boyd, S, Enting, D, Rudman, S, Ghosh, S, Karapanagiotou, E, Pintus, E, Tutt, A, Howlett, S, Brenton, J, Caldas, C, Fitzgerald, R, Jimenez-Linan, M, Provenzano, E, Cluroe, A, Paterson, A, Aitken, S, Allinson, K, Stewart, G, Mcdermott, U, Beddowes, E, Maughan, T, Ansorge, O, Campbell, P, Roxburgh, P, Fraser, S, Blyth, K, Le Quesne, J, Krebs, M, Blackhall, F, Summers, Y, Oliveira, P, Ortega-Franco, A, Dive, C, Gomes, F, Carter, M, Dransfield, J, Thomas, A, Fennell, D, Shaw, J, Wilson, C, Marrone, D, Naidu, B, Baijal, S, Tanchel, B, Langman, G, Robinson, A, Collard, M, Cockcroft, P, Ferris, C, Bancroft, H, Kerr, A, Middleton, G, Webb, J, Kadiri, S, Colloby, P, Olisemeke, B, Wilson, R, Shackleford, H, Osman, A, Tomlinson, I, Jogai, S, Holden, S, Fernandes, T, Mcneish, I, Hampton, B, Mckenzie, M, Hackshaw, A, Sharp, A, Chan, K, Farrelly, L, Bridger, H, Leslie, R, Tookman, A, Swanton, C, Jamal-Hanjani, M, Lise, S, Sandhu, S, Attard, G, Hasan A. M. M., Cremaschi P., Wetterskog D., Jayaram A., Wong S. Q., Williams S., Pasam A., Trigos A., Trujillo B., Grist E., Friedrich S., Vainauskas O., Parry M., Ismail M., Devlies W., Wingate A., Linch M., Naceur-Lombardelli C., Zaccaria S., Hessey S., Shiu K. -K., Bridgewater J., Hochhauser D., Forster M., Lee S. -M., Ahmad T., Papadatos-Pastos D., Janes S., Van Loo P., Enfield K., McGranahan N., Huebner A., Quezada S., Beck S., Parker P., Enver T., Hynds R. E., Pearce D. R., Falzon M., Proctor I., Sinclair R., Lok C. -W., Rhodes Z., Moore D., Marafioti T., Mitchison M., Ellery P., Sivakumar M., Brandner S., Rowan A., Hiley C., Veeriah S., Shaw H., Toncheva A., Prymas P., Watkins T. B. K., Bailey C., Martinez Ruiz C., Litchfield K., Al-Bakir M., Kanu N., Ward S., Lim E., Reading J., Chain B., Watkins T., Akay M., Flanagan A., Biswas D., Pich O., Dietzen M., Puttick C., Colliver E., Magness A., Angelova M., Black J., Lucas O., Hill W., Liu W. -K., Frankell A., Magno N., Athanasopoulou F., Salgado R., Lee C., Grigoriadis K., Al-Sawaf O., Karasaki T., Bunkum A., Noorani I., Benafif S., Barbe V., Bola S. K., Leone G., Alifrangis C., McGovern U., Thol K., Gamble S., Ung S. K., Sahwangarrom T., Marin C. P., Wong S., Pawlik P., Lam J. M., Richard C., Vendramin R., Dijkstra K., Rane J., Nicod J., Dwornik A., Bowles K., Zaidi R., Gishen F., Stone P., Stirling C., Turajlic S., Larkin J., Pickering L., Furness A., Young K., Drake W., Edmonds K., Hunter N., Mangwende M., Pearce K., Grostate L., Au L., Spain L., Shepherd S., Yan H., Shum B., Tippu Z., Hanley B., Spencer C., Emmerich M., Gerard C., Schmitt A. M., Del Rosario L., Carlyle E., Lewis C., Holt L., Lucanas A., O'Flaherty M., Hazell S., Mudhar H., Messiou C., Latifoltojar A., Fendler A., Byrne F., Pallikonda H., Lobon I., Coulton A., Cattin A. -L., Deng D., Feng H., Yousaf N., Popat S., Curtis O., Milner-Watts C., Stamp G., Nye E., Murra A., Korteweg J., Kelly D., Terry L., Biano J., Peat K., Kelly K., Grieco C., Le M. L., D'Arienzo P. D., Turay E., Hill P., Josephs D., Irshad S., Spicer J., Mahadeva U., Green A., Stewart R., Wright N., Pulman G., Mitu R., Phillips-Boyd S., Enting D., Rudman S., Ghosh S., Karapanagiotou E., Pintus E., Tutt A., Howlett S., Brenton J., Caldas C., Fitzgerald R., Jimenez-Linan M., Provenzano E., Cluroe A., Paterson A., Aitken S., Allinson K., Stewart G., McDermott U., Beddowes E., Maughan T., Ansorge O., Campbell P., Roxburgh P., Fraser S., Blyth K., Le Quesne J., Krebs M., Blackhall F., Summers Y., Oliveira P., Ortega-Franco A., Dive C., Gomes F., Carter M., Dransfield J., Thomas A., Fennell D., Shaw J., Wilson C., Marrone D., Naidu B., Baijal S., Tanchel B., Langman G., Robinson A., Collard M., Cockcroft P., Ferris C., Bancroft H., Kerr A., Middleton G., Webb J., Kadiri S., Colloby P., Olisemeke B., Wilson R., Shackleford H., Osman A., Tomlinson I., Jogai S., Holden S., Fernandes T., McNeish I., Hampton B., McKenzie M., Hackshaw A., Sharp A., Chan K., Farrelly L., Bridger H., Leslie R., Tookman A., Swanton C., Jamal-Hanjani M., Lise S., Sandhu S., and Attard G.

Abstract

Despite initial responses to hormone treatment, metastatic prostate cancer invariably evolves to a lethal state. To characterize the intra-patient evolutionary relationships of metastases that evade treatment, we perform genome-wide copy number profiling and bespoke approaches targeting the androgen receptor (AR) on 167 metastatic regions from 11 organs harvested post-mortem from 10 men who died from prostate cancer. We identify diverse and patient-unique alterations clustering around the AR in metastases from every patient with evidence of independent acquisition of related genomic changes within an individual and, in some patients, the co-existence of AR-neutral clones. Using the genomic boundaries of pan-autosome copy number changes, we confirm a common clone of origin across metastases and diagnostic biopsies, and identified in individual patients, clusters of metastases occupied by dominant clones with diverged autosomal copy number alterations. These autosome-defined clusters are characterized by cluster-specific AR gene architectures, and in two index cases are topologically more congruent than by chance (p-values 3.07 × 10−8 and 6.4 × 10−4). Integration with anatomical sites suggests patterns of spread and points of genomic divergence. Here, we show that copy number boundaries identify treatment-selected clones with putatively distinct lethal trajectories.

Published
2023

16. Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study

Author

Merseburger, A., primary, Faria, R., additional, Bahl, A., additional, Attard, G., additional, Snijder, R., additional, Sodatonou, H., additional, Pranzo, A., additional, Martins, K., additional, Rozario, N., additional, Flach, C., additional, Ridsdale-Smith, J., additional, and Chilelli, A., additional

Published
2023
Full Text
View/download PDF

17. Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Hakansson, A., additional, Van der Eecken, K., additional, Song, Y., additional, Liu, Y., additional, Fonteyne, V., additional, Verbeke, S., additional, Song, D., additional, Ross, A.E., additional, Feng, F.Y., additional, Gillessen, S., additional, Attard, G., additional, James, N., additional, Lotan, T.L., additional, Davicioni, E., additional, Sweeney, C., additional, Tran, P.T., additional, Deek, M.P., additional, and Ost, P., additional

Published
2023
Full Text
View/download PDF

18. Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer

Author

Sutera, P., primary, Shetty, A., additional, Song, Y., additional, Hodges, T., additional, Hoang, T., additional, Rana, Z.H., additional, Pienta, K., additional, Feng, F.Y., additional, Song, D., additional, DeWeese, T.L., additional, Gillessen, S., additional, James, N., additional, Attard, G., additional, Deek, M.P., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

19. Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

Author

Phillips, R., primary, Proudfoot, J., additional, Davicioni, E., additional, Spratt, D.E., additional, Feng, F.Y., additional, Simko, J., additional, Den, R.B., additional, Pollack, A., additional, Rosenthal, S.A., additional, Sartor, O., additional, Sweeney, C., additional, Attard, G., additional, Patel, S.I., additional, Hall, W.A., additional, Efstathiou, J.A., additional, Shah, A.B., additional, Hoffman, K.E., additional, Pugh, S., additional, Sandler, H.M., additional, and Tran, P.T., additional

Published
2023
Full Text
View/download PDF

20. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Author

Sydes, M.R., Spears, M.R., Mason, M.D., Clarke, N.W., Dearnaley, D.P., de Bono, J.S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Malik, Z.I., Jones, R., Parker, C.C., Ritchie, A.W.S., Russell, J.M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D.C., Hughes, R., McLaren, D., Lester, J.F., Nikapota, A., O’Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S.M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M.K.B., and James, N.D.

Published
2018
Full Text
View/download PDF

21. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters

Author

Linch, M., Goh, G., Hiley, C., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y.N.S., King, H., Furness, A., Freeman, A., Linares, J., Akarca, A., Herrero, J., Rosenthal, R., Harder, N., Schmidt, G., Wilson, G.A., Birkbak, N.J., Mitter, R., Dentro, S., Cathcart, P., Arya, M., Johnston, E., Scott, R., Hung, M., Emberton, M., Attard, G., Szallasi, Z., Punwani, S., Quezada, S.A., Marafioti, T., Gerlinger, M., Ahmed, H.U., and Swanton, C.

Published
2017
Full Text
View/download PDF

23. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.

Abstract

Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

24. ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses

Author

Ahmed, H.U., primary, Frangou, E., additional, Marsden, T., additional, Moore, C., additional, Shonit, P., additional, Singh, P., additional, Brew-Graves, C., additional, Clow, R., additional, Freeman, A., additional, Hadley, J., additional, Rawlins, F., additional, Santaolalla, A., additional, Rodriguez-Justo, M., additional, Syer, T., additional, Tuck, S., additional, Wingate, A., additional, Van Hemelrijk, M., additional, Attard, G., additional, Brown, L., additional, and Emberton, M., additional

Published
2023
Full Text
View/download PDF

25. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Author

Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., and Tombal, B.

Published
2015
Full Text
View/download PDF

28. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes

Author

Loveday, C., primary, Garrett, A., additional, Law, P., additional, Hanks, S., additional, Poyastro-Pearson, E., additional, Adlard, J.W., additional, Barwell, J., additional, Berg, J., additional, Brady, A.F., additional, Brewer, C., additional, Chapman, C., additional, Cook, J., additional, Davidson, R., additional, Donaldson, A., additional, Douglas, F., additional, Greenhalgh, L., additional, Henderson, A., additional, Izatt, L., additional, Kumar, A., additional, Lalloo, F., additional, Miedzybrodzka, Z., additional, Morrison, P.J., additional, Paterson, J., additional, Porteous, M., additional, Rogers, M.T., additional, Walker, L., additional, Eccles, D., additional, Evans, D.G., additional, Snape, K., additional, Hanson, H., additional, Houlston, R.S., additional, Turnbull, C., additional, Ardern-Jones, A., additional, Adlard, J., additional, Ahmed, M., additional, Attard, G., additional, Bailey, K., additional, Bancroft, E., additional, Bardsley, C., additional, Barton, D., additional, Bartlett, M., additional, Baxter, L., additional, Belk, R., additional, Bernhard, B., additional, Bishop, T., additional, Boyes, L., additional, Bradshaw, N., additional, Brant, S., additional, Brice, G., additional, Bromilow, G., additional, Brooks, C., additional, Bruce, A., additional, Bulman, B., additional, Burgess, L., additional, Campbell, J., additional, Canham, N., additional, Castle, B., additional, Cetnarskyj, R., additional, Claber, O., additional, Coates, N., additional, Cole, T., additional, Collins, A., additional, Coulson, S., additional, Crawford, G., additional, Cruger, D., additional, Cummings, C., additional, D’Mello, L., additional, Day, L., additional, Dell, B., additional, Dolling, C., additional, Dorkins, H., additional, Downing, S., additional, Drummond, S., additional, Dubras, C., additional, Dunlop, J., additional, Durrell, S., additional, Eddy, C., additional, Edwards, M., additional, Edwards, E., additional, Edwardson, J., additional, Eeles, R., additional, Ellis, I., additional, Elmslie, F., additional, Evans, G., additional, Gibbons, B., additional, Gardiner, C., additional, Ghali, N., additional, Giblin, C., additional, Gibson, S., additional, Goff, S., additional, Goodman, S., additional, Goudie, D., additional, Grier, J., additional, Gregory, H., additional, Halliday, S., additional, Hardy, R., additional, Hartigan, C., additional, Heaton, T., additional, Higgins, C., additional, Hodgson, S., additional, Homfray, T., additional, Horrigan, D., additional, Houghton, C., additional, Hughes, L., additional, Hunt, V., additional, Irvine, L., additional, Jacobs, C., additional, James, S., additional, James, M., additional, Jeffers, L., additional, Jobson, I., additional, Jones, W., additional, Kennedy, M.J., additional, Kenwrick, S., additional, Kightley, C., additional, Kirk, C., additional, Kirk, E., additional, Kivuva, E., additional, Kohut, K., additional, Kosicka-Slawinska, M., additional, Kulkarni, A., additional, Lambord, N., additional, Langman, C., additional, Leonard, P., additional, Levene, S., additional, Locker, S., additional, Logan, P., additional, Longmuir, M., additional, Lucassen, A., additional, Lyus, V., additional, Magee, A., additional, Male, A., additional, Mansour, S., additional, McBride, D., additional, McCann, E., additional, McConnell, V., additional, McEntagart, M., additional, McKeown, C., additional, McLeish, L., additional, McLeod, D., additional, Melville, A., additional, Mercer, L., additional, Mercer, C., additional, Mitra, A., additional, Murday, V., additional, Murray, A., additional, Myhill, K., additional, Myring, J., additional, O'Hara, E., additional, Pearson, P., additional, Pichert, G., additional, Platt, K., additional, Pottinger, C., additional, Price, S., additional, Protheroe, L., additional, Pugh, S., additional, Quarrell, O., additional, Randhawa, K., additional, Riddick, C., additional, Robertson, L., additional, Robinson, A., additional, Roffey-Johnson, V., additional, Rogers, M., additional, Rose, S., additional, Rowe, S., additional, Schofield, A., additional, Rahman, N., additional, Saya, S., additional, Scott, G., additional, Scott, J., additional, Searle, A., additional, Shanley, S., additional, Sharif, S., additional, Shaw, A., additional, Shaw, J., additional, Shea-Simonds, J., additional, Side, L., additional, Sillibourne, J., additional, Simon, K., additional, Simpson, S., additional, Slater, S., additional, Smalley, S., additional, Smith, K., additional, Snadden, L., additional, Soloway, J., additional, Stait, Y., additional, Stayner, B., additional, Steel, M., additional, Steel, C., additional, Stewart, H., additional, Stirling, D., additional, Thomas, M., additional, Thomas, S., additional, Tomkins, S., additional, Turner, H., additional, Vandersteen, A., additional, Wakeling, E., additional, Waldrup, F., additional, Watt, C., additional, Watts, S., additional, Webber, A., additional, Whyte, C., additional, Wiggins, J., additional, Williams, E., additional, and Winchester, L., additional

Published
2022
Full Text
View/download PDF

29. 158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study

Author

Binti Saad, M., primary, Chi, K.N., additional, Jung, W., additional, Pang, S-T., additional, Attard, G., additional, Sandhu, S.K., additional, Mason, G.E., additional, del Corral, A., additional, Wang, G., additional, Wu, D., additional, Diorio, B., additional, Lopez-Gitlitz, A., additional, and Lee, J.Y., additional

Published
2022
Full Text
View/download PDF

30. 1359MO Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE

Author

Haran, Á.M., primary, Jain, Y., additional, Hambrock, T., additional, Murphy, L.R., additional, Cook, A., additional, Brown, L.C., additional, Hoyle, A.P., additional, Sachdeva, A., additional, Ali, S.A., additional, Amos, C.L., additional, Sydes, M.R., additional, Attard, G., additional, Parmar, M.K., additional, James, N.D., additional, and Clarke, N.W., additional

Published
2022
Full Text
View/download PDF

31. LBA62 Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol

Author

Attard, G., primary, Murphy, L., additional, Clarke, N., additional, Cross, W., additional, Gillessen, S., additional, Amos, C., additional, Brawley, C., additional, Jones, R., additional, Pezaro, C., additional, Malik, Z., additional, Montazeri, A., additional, Millman, R., additional, Cook, A., additional, Gilbert, D., additional, Langley, R., additional, Parker, C., additional, Sydes, M., additional, Brown, L., additional, Parmar, M., additional, and James, N., additional

Published
2022
Full Text
View/download PDF

33. LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

Author

Conteduca, V., Brighi, N., Gurioli, G., Wetterskog, D., Giunta, E.F., Lolli, C., Schepisi, G., Chiuri, V.E., Gasparro, D., Zucali, P.A., Virga, A., Bondi, I., Vertogen, B., Di Iorio, V., Sansovini, M., Severi, S., Scarpi, E., Urbini, M., Attard, G., and De Giorgi, U.

Published
2024
Full Text
View/download PDF

34. LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE

Author

Gillessen, S., Murphy, L.R., James, N.D., Sachdeva, A., Attard, G., Jones, R.J., Adler, A., El-Taji, O., Varughese, M., Gale, J., Brown, S.J., Srihari, N.N., Millman, R., Matheson, D., Amos, C.L., Murphy, C., McAlpine, C., Parmar, M.K., Brown, L.C., and Clarke, N.

Published
2024
Full Text
View/download PDF

35. 1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)

Author

Padden-Modi, M., Abdel-Aty, H., Jones, C., Brown, L.C., Dutey-Magni, P., Yogeswaran, Y., Horsey, A., Amos, C.L., Murray, I., Hujairi, N., Tunariu, N., Millman, R., Cross, W., Kasivisvanathan, V., Parmar, M.K., Clarke, N., Gillessen, S., Attard, G., Parker, C., and James, N.D.

Published
2024
Full Text
View/download PDF

36. 1656TiP The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)

Author

Howlett, S., Kayani, M., Brown, L.C., Amos, C.L., Dutey-Magni, P., Yogeswaran, Y., O'Shea, L., Hogan, C., Wingate, A., Lall, S., Eeles, R., Hubank, M., Williams, P., Cross, W., Sachdeva, A., Clarke, N., Parmar, M.K., James, N.D., Grist, E., and Attard, G.

Published
2024
Full Text
View/download PDF

37. 1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)

Author

Abdel-Aty, H., Amos, C.L., Brown, L.C., Yogeswaran, Y., Niem, P., Dutey-Magni, P., Kasivisvanathan, V., Bennett, R., Clarke, N., Sachdeva, A., Cross, W., Farrelly, L., Matheson, D., Peedell, C., DIEZ, P., Naismith, O., Parmar, M.K., Attard, G., van As, N., and James, N.D.

Published
2024
Full Text
View/download PDF

39. 1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials

Author

Grist, E., Dutey-Magni, P., Mendes, L., Parry, M.A., Sachdeva, A., Proudfoot, J., Hamid, A.A., Amos, C.L., Cross, W., Gillessen, S., Berney, D.M., Sydes, M.R., Parmar, M.K., Feng, F., Clarke, N., Davicioni, E., Sweeney, C., James, N.D., Brown, L.C., and Attard, G.

Published
2024
Full Text
View/download PDF

41. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Turco, F, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, C, Clarke, N, Davis, ID, de Bono, J, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Onyeanunam, NE, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Pablo Sade, J, Sartor, O, Scher, H, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, D, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, M, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Gillessen, S, Omlin, A, Turco, F, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, C, Clarke, N, Davis, ID, de Bono, J, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Onyeanunam, NE, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Pablo Sade, J, Sartor, O, Scher, H, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, D, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, M, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Gillessen, S, and Omlin, A

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

Published
2022

42. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, CS, Clarke, N, Davis, ID, de Bono, JS, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ekeke, ON, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, H, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, DE, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, MR, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Omlin, A, Gillessen, S, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, CS, Clarke, N, Davis, ID, de Bono, JS, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Ekeke, ON, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, H, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, DE, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, MR, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, and Omlin, A

Abstract

BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. OBJECTIVE: To present the voting results from APCCC 2021. DESIGN, SETTING, AND PARTICIPANTS: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. RESULTS AND LIMITATIONS: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. CONCLUSIONS: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden

Published
2022

44. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S., Armstrong, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Oort, I.M. van, Zapatero, Almudena, Omlin, A., Gillessen, S., Armstrong, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Oort, I.M. van, Zapatero, Almudena, and Omlin, A.

Abstract

Contains fulltext : 251850.pdf (Publisher’s version ) (Open Access)

Published
2022

45. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Author

Pascual, J, Attard, G, Bidard, F-C, Curigliano, G, De Mattos-Arruda, L, Diehn, M, Italiano, A, Lindberg, J, Merker, JD, Montagut, C, Normanno, N, Pantel, K, Pentheroudakis, G, Popat, S, Reis-Filho, JS, Tie, J, Seoane, J, Tarazona, N, Yoshino, T, Turner, NC, Pascual, J, Attard, G, Bidard, F-C, Curigliano, G, De Mattos-Arruda, L, Diehn, M, Italiano, A, Lindberg, J, Merker, JD, Montagut, C, Normanno, N, Pantel, K, Pentheroudakis, G, Popat, S, Reis-Filho, JS, Tie, J, Seoane, J, Tarazona, N, Yoshino, T, and Turner, NC

Abstract

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society for Medical Oncology convened an expert working group to review the analytical and clinical validity and utility of ctDNA assays. For patients with advanced cancer, validated and adequately sensitive ctDNA assays have utility in identifying actionable mutations to direct targeted therapy, and may be used in routine clinical practice, provided the limitations of the assays are taken into account. Tissue-based testing remains the preferred test for many cancer patients, due to limitations of ctDNA assays detecting fusion events and copy number changes, although ctDNA assays may be routinely used when faster results will be clinically important, or when tissue biopsies are not possible or inappropriate. Reflex tumour testing should be considered following a non-informative ctDNA result, due to false-negative results with ctDNA testing. In patients treated for early-stage cancers, detection of molecular residual disease or molecular relapse, has high evidence of clinical validity in anticipating future relapse in many cancers. Molecular residual disease/molecular relapse detection cannot be recommended in routine clinical practice, as currently there is no evidence for clinical utility in directing treatment. Additional potential applications of ctDNA assays, under research development and not recommended for routine practice, include identifying patients not responding to therapy with early dynamic changes in ctDNA levels, monitoring therapy for the development of resistance mutations before clinical progression, and in screening asymptomatic people for cancer. Recommendations for reporting of results, future development of ctDNA assays and future clinical research are made.

Published
2022

46. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (vol 82, pg 6, 2022)

Author

Turco, F, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, C, Clarke, N, Davis, ID, de Bono, J, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ekeke, ON, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, HI, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, D, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, M, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Gillessen, S, Omlin, A, Turco, F, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, C, Clarke, N, Davis, ID, de Bono, J, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ekeke, ON, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Sade, JP, Sartor, O, Scher, HI, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, D, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, M, Taplin, M-E, Tilki, D, Tombal, B, Turkeri, L, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Gillessen, S, and Omlin, A

Published
2022

47. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden, National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022

48. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results